In 2012, practicing vascular surgeon, John P. Pigott, MD, FACS realized there was an unmet need in vessel preparation for the treatment of peripheral artery disease (PAD). With support from Promedica Innovations, Dr. Pigott founded the VentureMed Group to design, develop, and market cost-effective interventional devices to improve patient outcomes and reduce the overall cost of care for the provider and the procedure.
VentureMed Group has received ISO 13485 Certification for its Quality System.
Dr. Pigott is the founder and Chief Medical Officer of VentureMed. He is the past director of endovascular surgery at the Jobst Vascular Institute and current Chief Innovation Officer for ProMedica Health Systems in Toledo, Ohio. Dr. Pigott previously completed a fellowship in vascular surgery at the Mayo Clinic and involved with multiple product trainings with Boston Scientific, J&J, Cook, Abbott and Medtronic. With more than 75 peer-reviewed publications, podium presentations, and book chapter authorship to his credit, he has spent more than 20 years in the endovascular arena.
Mr. Paulson is president, chief executive officer and a director of the VentureMed Group. Mr. Paulson has more than twenty-three years of medical device leadership experience, including serving as president, CEO and a director at NxThera and Restore Medical, and in a variety of executive leadership roles at Endocardial Solutions, Advanced Bionics and Medtronic. Prior to joining the medical device industry, Mr. Paulson held a variety of senior marketing, business development, legal and finance positions at General Mills, and as an attorney with the law firm of Lindquist & Vennum. Mr. Paulson currently serves as a director of Veran Medical Technologies and Spineology, is vice chair of the Luther College Board of Regents and previously served as a director on the boards of several public and privately held medical device companies and charitable foundations. Mr. Paulson received a JD from the Vanderbilt University School of Law, an MBA from the University of St. Thomas.
Mr. Cox has over 25 years of experience in medical device and biotech pharmaceutical sales and sales management including 19 years in the endovascular device space. From 2013 to 2016, Mr. Cox was Vice President of Sales, Sales Operations and Sales Training for Covidien's peripheral teams leading both the endo-arterial and endo-venous businesses. In 2016, post buy-out, he strategically guided the ev3 peripheral portfolios from Covidien to Medtronic. Over his career, Mr. Cox has led expansions of sales teams, integrations post company mergers, and launched new innovative technologies and key product portfolio extensions. Previously he served as Regional Sales Manager, Area Director of Sales, and Senior Director of Corporate Accounts for Covidien, ev3, and Microvena. Mr. Cox received a BBA in Business Administration from James Madison University.
Ms. Schweiger is the vice president of clinical, regulatory, and quality assurance at VentureMed. She has more than thirty years of experience in the medical device industry, with the majority of her career focused in venture capital-funded, early-stage medical device companies. Most recently, Ms. Schweiger led execution of the global regulatory, QA, and clinical strategies at Medovex. She previously held executive positions and responsibilities at Flowonix Medical, Angel Medical Systems, and several companies acquired by J&J, Teramed, IsoStent, and Gynecare. She spent the early part of her career with Baxter Healthcare and Eli Lilly. Ms. Schweiger received a BS in Mechanical Engineering from Virginia Polytechnic Institute and State University (Virginia Tech).
Ms. Hautman is the chief financial officer at VentureMed. She brings nearly 30 years of financial experience in the medical device, insurance administration, and venture capital industries. Most recently, Ms. Hautman served as the chief financial officer for Three Wire Inc., a patient recruitment firm. Prior to Three Wire, Inc., held senior finance and controller positions at Award Staffing, CoAxia, Raymedica, Inc., DRIASI, and Pathfinder Venture Capital Funds. She received a BS in Business, Accounting from the University of Minnesota, Carlson School of Management.
Ms. Zeroni is the vice president of R&D and Operations at VentureMed. She brings 17 years of medical device research and development experience to the company, most recently as the Director of R&D and PMO at Stryker, leading the development and integration of ENT products. Ms. Zeroni has led R&D/Operations groups through successful integration and technology transfer including 510k and PMA devices (Fox Hallow to Covidien, CV Ingenuity to SPNC and Entellus to Stryker). Her background includes building Operations teams from the ground up including successful launches of several devices in the vascular space with PTA and atherectomy devices (EV3/COV), Drug coated balloon (Spectranetics), drug coated Stents and other implants (Surmodics). Ms. Zeroni served in the Israeli Defense Forces and also received a BS in Chemical Engineering at Ben-Gurion University (Israel) and MS in Chemical Engineering from Ben-Gurion University (Israel) partnering with the Max Planck Institute (Germany).